Oesophageal carcinoma

[1]  Carissa A. Sanchez,et al.  Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. , 2005, The Lancet. Oncology.

[2]  Shu-Juan Yang,et al.  Genetic polymorphisms of ADH2 and ALDH2 association with esophageal cancer risk in southwest China. , 2007, World journal of gastroenterology.

[3]  H. El‐Serag,et al.  Temporal trends (1973–1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? , 2003, American Journal of Gastroenterology.

[4]  H. Barr,et al.  Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base , 2006, BMJ : British Medical Journal.

[5]  C. Camargo,et al.  Body-mass index and symptoms of gastroesophageal reflux in women. , 2006, The New England journal of medicine.

[6]  Ming-Tsang Wu,et al.  Carcinogenetic impact of alcohol intake on squamous cell carcinoma risk of the oesophagus in relation to tobacco smoking. , 2007, European journal of cancer.

[7]  D. Mathisen,et al.  Transthoracic esophagectomy: a safe approach to carcinoma of the esophagus. , 1988, The Annals of thoracic surgery.

[8]  H. Welch,et al.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. , 2005, Journal of the National Cancer Institute.

[9]  Stefan Vogt,et al.  Zinc concentration in esophageal biopsy specimens measured by x-ray fluorescence and esophageal cancer risk. , 2005, Journal of the National Cancer Institute.

[10]  Suzanne S Gisbertz,et al.  Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial , 2012, The Lancet.

[11]  M. Iannettoni,et al.  Transhiatal esophagectomy: clinical experience and refinements. , 1999, Annals of surgery.

[12]  M. Gail,et al.  Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. , 1993, Journal of the National Cancer Institute.

[13]  D. Miller,et al.  Ivor Lewis esophagogastrectomy for esophageal cancer. , 2001, The Annals of thoracic surgery.

[14]  T. Rice.  DIAGNOSIS AND STAGING OF ESOPHAGEAL CANCER , 2008 .

[15]  M. Blaser,et al.  Population attributable risks of esophageal and gastric cancers. , 2003, Journal of the National Cancer Institute.

[16]  N. Altorki,et al.  Three-Field Lymph Node Dissection for Squamous Cell and Adenocarcinoma of the Esophagus , 2002, Annals of surgery.

[17]  S. Tsugane,et al.  A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. , 1997, The Journal of thoracic and cardiovascular surgery.

[18]  Patricia L. Blount,et al.  Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables , 2001, American Journal of Gastroenterology.

[19]  Noel S Weiss,et al.  Surveillance and survival in Barrett's adenocarcinomas: a population-based study. , 2002, Gastroenterology.

[20]  D. R. Jones.  The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: Results of the American College of Surgeons Oncology Group Z0060 trial , 2008 .

[21]  T. Nishihira,et al.  A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. , 1998, American journal of surgery.

[22]  P. Enzinger,et al.  Irinotecan in esophageal cancer. , 2000, Oncology.

[23]  J. Luketich,et al.  Surgical aspects of the patient with high-grade dysplasia. , 2005, Seminars in Thoracic and Cardiovascular Surgery.

[24]  J. Going,et al.  Systematic Four-Quadrant Biopsy Detects Barrett's Dysplasia in More Patients Than Nonsystematic Biopsy , 2008, The American Journal of Gastroenterology.

[25]  Nils Lehmann,et al.  Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Abnet,et al.  Prospective study of tooth loss and incident esophageal and gastric cancers in China , 2001, Cancer Causes and Control.

[27]  S. Spechler,et al.  Clinical practice. Barrett's Esophagus. , 2002, The New England journal of medicine.

[28]  D. Johnson,et al.  Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety , 2001, American Journal of Gastroenterology.

[29]  D. Corley,et al.  Body Mass Index and Adenocarcinomas of the Esophagus or Gastric Cardia: A Systematic Review and Meta-analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.

[30]  D. Morgan,et al.  The Burden of Gastrointestinal and Liver Diseases, 2006 , 2006, The American Journal of Gastroenterology.

[31]  Judy L. Smith,et al.  Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  W. Budach,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.

[33]  M. Bronner,et al.  Central adiposity and risk of Barrett's esophagus. , 2007, Gastroenterology.

[34]  B. Reid,et al.  Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis , 2010, Nature Reviews Cancer.

[35]  P. Kahrilas,et al.  Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. , 2000, Gastroenterology.

[36]  D. Skinner,et al.  Barrett's esophagus. Functional assessment, proposed pathogenesis, and surgical therapy. , 1983, Archives of surgery.

[37]  J. Ajani,et al.  Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer : A Report of the V 325 Study Group , 2006 .

[38]  D. Gotley,et al.  Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus , 2007, Gut.

[39]  C. V. Van Itallie,et al.  Claudin-18: a dominant tight junction protein in Barrett's esophagus and likely contributor to its acid resistance. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[40]  J. Cooper,et al.  Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. , 1992, The New England journal of medicine.

[41]  Michael B Wallace,et al.  Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett's Esophagus. , 2008, Gastroenterology.

[42]  Aller,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2002, The New England journal of medicine.

[43]  A. Smout,et al.  Laparoscopic or conventional Nissen fundoplication for gastrooesophageal reflux disease: randomised clinical trial , 2000, The Lancet.

[44]  C. Abnet,et al.  Prospective study of serum vitamin E levels and esophageal and gastric cancers. , 2003, Journal of the National Cancer Institute.

[45]  D. Faigel,et al.  Biopsy-negative malignant esophageal stricture: diagnosis by endoscopic ultrasound , 1998, American Journal of Gastroenterology.

[46]  T. Godfrey,et al.  Molecular staging of lymph nodes from patients with esophageal adenocarcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  V. Rusch,et al.  The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. , 2007, The Journal of thoracic and cardiovascular surgery.

[48]  L. Johnson,et al.  Risk factors for esophagitis in extreme acid hypersecretors with and without Zollinger-Ellison syndrome. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[49]  J. Luketich,et al.  Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. , 2008, The Annals of thoracic surgery.

[50]  J. Bosset,et al.  Chemotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus , 1998 .

[51]  A. Stewart,et al.  Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. , 2000, Journal of the American College of Surgeons.

[52]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[53]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[54]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Peter D Siersema,et al.  Esophageal cancer. , 2008, Gastroenterology clinics of North America.

[56]  M. Clementi,et al.  The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study , 2005, Alimentary pharmacology & therapeutics.

[57]  P. Puttisak,et al.  A prospective study of combined therapy in esophageal cancer. , 1994, Hepato-gastroenterology.

[58]  R. Sampliner,et al.  Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. , 2001, JAMA.

[59]  H. El‐Serag,et al.  Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. , 2008, Gastrointestinal endoscopy.

[60]  R. Sandler,et al.  Is there publication bias in the reporting of cancer risk in Barrett's esophagus? , 2000, Gastroenterology.

[61]  W. Chow,et al.  Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. , 2001, Gastroenterology.

[62]  R. Hunt,et al.  Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. , 1997, Gastroenterology.

[63]  E. Furth,et al.  Carcinoma of the esophagus and esophagogastric junction: sensitivity of radiographic diagnosis. , 1997, AJR. American journal of roentgenology.

[64]  B. Dean,et al.  Effectiveness of proton pump inhibitors in nonerosive reflux disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[65]  M. Gammon,et al.  Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. , 1997, Journal of the National Cancer Institute.

[66]  D. Forman.  Re: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. , 2005, Journal of the National Cancer Institute.

[67]  T. Humphries,et al.  Famotidine Relieves Symptoms of Gastroesophageal Reflux Disease and Heals Erosions and Ulcerations: Results of a Multicenter, Placebo-Controlled, Dose-Ranging Study , 1991 .

[68]  Janusz Jankowski,et al.  A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. , 2004, Gastroenterology.

[69]  Peter J. Pronovost,et al.  Intensive care unit physician staffing is associated with decreased length of stay, hospital cost, and complications after esophageal resection , 2001, Critical care medicine.

[70]  Kenneth K Wang,et al.  Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus , 1998, The American Journal of Gastroenterology.

[71]  P. D. De Leyn,et al.  Three-Field Lymphadenectomy for Carcinoma of the Esophagus and Gastroesophageal Junction in 174 R0 Resections: Impact on Staging, Disease-Free Survival, and Outcome: A Plea for Adaptation of TNM Classification in Upper-Half Esophageal Carcinoma , 2004, Annals of surgery.

[72]  Chuanshu Huang,et al.  Cancer prevention with freeze-dried berries and berry components. , 2007, Seminars in cancer biology.

[73]  J. Luketich,et al.  Results of expandable metal stents for malignant esophageal obstruction in 100 patients: short-term and long-term follow-up. , 2001, The Annals of thoracic surgery.

[74]  H. McElroy,et al.  Adenocarcinoma of the oesophagus: incidence and survival rates in New South Wales, 1972–2005 , 2009, The Medical journal of Australia.

[75]  A. Polednak,et al.  Trends in survival for both histologic types of esophageal cancer in U.S. surveillance, epidemiology and end results areas , 2003, International journal of cancer.

[76]  P. Parrilla,et al.  Long-Term Results of a Randomized Prospective Study Comparing Medical and Surgical Treatment of Barrett’s Esophagus , 2003, Annals of surgery.

[77]  V. Rusch,et al.  A cancer staging primer: esophagus and esophagogastric junction. , 2010, The Journal of thoracic and cardiovascular surgery.

[78]  J. Reitsma,et al.  Extended Transthoracic Resection Compared With Limited Transhiatal Resection for Adenocarcinoma of the Mid/Distal Esophagus: Five-Year Survival of a Randomized Clinical Trial , 2007, Annals of surgery.

[79]  P D Schneider,et al.  Comparison of minimally invasive esophagectomy with transthoracic and transhiatal esophagectomy. , 2000, Archives of surgery.

[80]  Michael Vieth,et al.  Prevalence of Barrett's esophagus in the general population: an endoscopic study. , 2005, Gastroenterology.

[81]  M. Luostarinen,et al.  The long term results of open antireflux surgery in a community-based health care center , 1999, American Journal of Gastroenterology.

[82]  A. Poynton,et al.  Carcinoma arising in familial Barrett's esophagus. , 1996, The American journal of gastroenterology.

[83]  R. Hinder,et al.  Bowel dysfunction after laparoscopic antireflux surgery: incidence, severity, and clinical course. , 2003, The American journal of medicine.

[84]  Alex G. Little,et al.  Obesity Correlates with Gastroesophageal Reflux , 1999, Digestive Diseases and Sciences.

[85]  B. Reid,et al.  Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. , 1988, Gastroenterology.

[86]  E. Kuipers,et al.  Aneuploidy and Overexpression of Ki67 and p53 as Markers for Neoplastic Progression in Barrett's Esophagus: A Case–Control Study , 2009, The American Journal of Gastroenterology.

[87]  S. Franceschi,et al.  EPIDEMIOLOGY OF ESOPHAGEAL CANCER , 2013 .

[88]  N. Day,et al.  NO EFFECT OF RIBOFLAVINE, RETINOL, AND ZINC ON PREVALENCE OF PRECANCEROUS LESIONS OF OESOPHAGUS Randomised Double-blind Intervention Study in High-risk Population of China , 1985, The Lancet.

[89]  D. Castell,et al.  Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. , 1998, Gastroenterology.

[90]  N. Vakil,et al.  Clinical effectiveness of laparoscopic fundoplication in a U.S. community. , 2003, The American journal of medicine.

[91]  Jesper Lagergren,et al.  Association between Medications That Relax the Lower Esophageal Sphincter and Risk for Esophageal Adenocarcinoma , 2000, Annals of Internal Medicine.

[92]  P. Moayyedi,et al.  Gastro-oesophageal refl ux disease , 2006 .

[93]  R C Heading,et al.  Barrett's oesophagus. , 1987, British medical journal.

[94]  A. Huang,et al.  Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies , 2004, Canadian Medical Association Journal.

[95]  Ghulam Abbas,et al.  Outcomes After Minimally Invasive Esophagectomy: Review of Over 1000 Patients , 2012, Annals of surgery.

[96]  A. Csendes,et al.  [Chemotherapy of esophageal cancer]. , 1984, Revista medica de Chile.

[97]  Hiroshi Mashimo,et al.  Radiofrequency ablation in Barrett's esophagus with dysplasia. , 2009, The New England journal of medicine.

[98]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[99]  H. Yamana,et al.  Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  Wolfgang A Weber,et al.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. , 2007, The Lancet. Oncology.

[101]  L. Kleinberg,et al.  Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization , 2007, Nature Clinical Practice Oncology.

[102]  J. Ajani,et al.  Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. , 1998, The New England journal of medicine.

[103]  A. Benson,et al.  Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  P. Schauer,et al.  Minimally invasive surgical staging is superior to endoscopic ultrasound in detecting lymph node metastases in esophageal cancer. , 1997, The Journal of thoracic and cardiovascular surgery.

[105]  A. Krasinskas,et al.  Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. , 2009, The Annals of thoracic surgery.

[106]  A. Sonnenberg,et al.  Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. , 2001, Gastroenterology.

[107]  J. Dent,et al.  The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus , 2006, The American Journal of Gastroenterology.

[108]  M. Mazumdar,et al.  Multifocal Neoplasia and Nodal Metastases in T1 Esophageal Carcinoma: Implications for Endoscopic Treatment , 2008, Annals of surgery.

[109]  Walsh,et al.  Review article: potential gastrointestinal effects of long‐term acid suppression with proton pump inhibitors , 2000, Alimentary pharmacology & therapeutics.

[110]  A. Kristal,et al.  Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[111]  V. Gebski,et al.  Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. , 2005, The Lancet. Oncology.

[112]  D. Ransohoff,et al.  Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. , 2002, JAMA.

[113]  J. Tijssen,et al.  Transthoracic Versus Transhiatal Resection for Carcinoma of the Esophagus , 2007 .

[114]  H. Comber,et al.  Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. , 2007, World journal of gastroenterology.

[115]  J. Jankowski,et al.  Chemoprevention of oesophageal cancer and the AspECT trial. , 2009, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[116]  A. Sonnenberg,et al.  Opposing time trends of peptic ulcer and reflux disease , 1998, Gut.

[117]  R. Hunt,et al.  Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[118]  L. Saltz,et al.  Irinotecan and cisplatin in upper gastrointestinal malignancies. , 1998, Oncology.

[119]  J. Birkmeyer,et al.  Hospital volume and surgical mortality in the United States. , 2002, The New England journal of medicine.

[120]  A. Ruigómez,et al.  Gastric Acid, Acid‐Suppressing Drugs, and Bacterial Gastroenteritis: How Much of a Risk? , 1997, Epidemiology.

[121]  J. Luketich,et al.  CALGB 9380: a prospective trial of the feasibility of thoracoscopy/laparoscopy in staging esophageal cancer. , 2001, The Annals of thoracic surgery.

[122]  J. Guirguis-Blake.  Medical treatments in the short-term management of reflux esophagitis. , 2008, American family physician.

[123]  Lucia M. A. Crane,et al.  Oesophageal cancer in The Netherlands: increasing incidence and mortality but improving survival. , 2007, European journal of cancer.

[124]  J. Pandolfino,et al.  Esophagogastric junction opening during relaxation distinguishes nonhernia reflux patients, hernia patients, and normal subjects. , 2003, Gastroenterology.

[125]  J. Luketich,et al.  Endoscopic ultrasound compared with laparoscopy for staging esophageal cancer. , 2007, The Annals of thoracic surgery.

[126]  A. Gaast,et al.  First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study , 2007, British Journal of Cancer.

[127]  J. Ajani,et al.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  S. Spechler,et al.  Hallmarks of cancer progression in Barrett's oesophagus , 2002, The Lancet.

[129]  A. Neugut,et al.  Radiation Therapy for Breast Cancer and Increased Risk for Esophageal Carcinoma , 1998, Annals of Internal Medicine.

[130]  J. Dent,et al.  Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. , 2000, Gastroenterology.

[131]  J. Luketich,et al.  The "best operation" for esophageal cancer? , 2010, The Annals of thoracic surgery.

[132]  D. Girling.  Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial , 2002, The Lancet.

[133]  L. Lundell,et al.  Seven‐year follow‐up of a randomized clinical trial comparing proton‐pump inhibition with surgical therapy for reflux oesophagitis , 2007, The British journal of surgery.

[134]  L. Schwartz,et al.  Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  G. Maddern,et al.  Oesophagectomy by a transhiatal approach or thoracotomy: A prospective randomized trial , 1993, The British journal of surgery.

[136]  A. Lindgren,et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.

[137]  Peter J. Richardson,et al.  Fundoplication and the Risk of Esophageal Cancer in Gastroesophageal Reflux Disease: A Veterans Affairs Cohort Study , 2005, The American Journal of Gastroenterology.

[138]  M. Samsom,et al.  Gastroesophageal Pressure Gradients in Gastroesophageal Reflux Disease: Relations With Hiatal Hernia, Body Mass Index, and Esophageal Acid Exposure , 2008, The American Journal of Gastroenterology.

[139]  Seth D. Crockett,et al.  Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. , 2005, Archives of internal medicine.

[140]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[141]  W. Hop,et al.  Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. , 1995, Gut.

[142]  W. Chow,et al.  Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. , 2008, Journal of the National Cancer Institute.

[143]  homas,et al.  A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma , 2000 .

[144]  Yu-Xiao Yang,et al.  Long-term proton pump inhibitor therapy and risk of hip fracture. , 2006, JAMA.

[145]  M. Hollstein,et al.  The tylosis esophageal cancer (TOC) locus: more than just a familial cancer gene. , 1999, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[146]  Michael Vieth,et al.  Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). , 2005, Gastrointestinal endoscopy.

[147]  D. Sugarbaker,et al.  Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. , 2001, The Annals of thoracic surgery.

[148]  G. Block,et al.  Abdominal obesity and body mass index as risk factors for Barrett's esophagus. , 2007, Gastroenterology.

[149]  V. Rusch,et al.  The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. , 2006, The Journal of thoracic and cardiovascular surgery.

[150]  E. Korn,et al.  Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. , 2005, Gastroenterology.

[151]  E. Kuipers,et al.  Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. , 2010, The Cochrane database of systematic reviews.

[152]  J. Dent,et al.  Review article: from 1906 to 2006 – a century of major evolution of understanding of gastro‐oesophageal reflux disease , 2006, Alimentary pharmacology & therapeutics.

[153]  R. van Hillegersberg,et al.  Minimally invasive surgery compared to open procedures in esophagectomy for cancer: a systematic review of the literature. , 2009, Minerva chirurgica.

[154]  A. Shar,et al.  Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. , 2007, Journal of the National Cancer Institute.

[155]  T. Rösch,et al.  Endosonographic staging of esophageal cancer: a review of literature results. , 1995, Gastrointestinal endoscopy clinics of North America.

[156]  Tasha A K Gandamihardja,et al.  Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. , 2006, Journal of the American College of Surgeons.

[157]  M. Iannettoni,et al.  Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[158]  E. Stefani,et al.  Black (air-cured) and blond (flue-cured) tobacco and cancer risk. III: Oesophageal cancer. , 1993, European journal of cancer.

[159]  F. Islami,et al.  Helicobacter pylori and Esophageal Cancer Risk: A Meta-analysis , 2008, Cancer Prevention Research.

[160]  K. Chu,et al.  A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. , 1997, American journal of surgery.

[161]  M. Coleman,et al.  Continuing Rapid Increase in Esophageal Adenocarcinoma in England and Wales , 2008, The American Journal of Gastroenterology.

[162]  Paul Fockens,et al.  Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. , 2002, The New England journal of medicine.

[163]  M. Hassel,et al.  A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus , 1994, Cancer.

[164]  T. Walsh,et al.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. , 1996, The New England journal of medicine.

[165]  J. Dominitz,et al.  Complications and antireflux medication use after antireflux surgery. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[166]  J. Luketich,et al.  Photodynamic therapy as palliation for esophageal cancer: experience in 215 patients. , 2003, The Annals of thoracic surgery.

[167]  M Dosemeci,et al.  Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. , 2000, American journal of epidemiology.

[168]  J. Luketich,et al.  Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. , 1999, The Annals of thoracic surgery.

[169]  J. Luketich,et al.  Resection for esophageal cancer: strategies for optimal management. , 2008, The Annals of thoracic surgery.

[170]  N. Shaheen,et al.  Does screening for Barrett's esophagus and adenocarcinoma of the esophagus prolong survival? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[171]  R. Landreneau,et al.  Esophageal palliation--photodynamic therapy/stents/brachytherapy. , 2005, The Surgical clinics of North America.

[172]  R. Cestari,et al.  Long-term endoscopic surveillance of patients with Barrett's esophagus. incidence of dysplasia and adenocarcinoma: a prospective study , 2003, American Journal of Gastroenterology.

[173]  D. Sugarbaker,et al.  Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  N. Shaheen,et al.  Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis , 2003, American Journal of Gastroenterology.

[175]  D. Fleischer,et al.  Esophageal cancer: epidemiology, pathogenesis and prevention , 2008, Nature Clinical Practice Gastroenterology &Hepatology.

[176]  J. Peters,et al.  Curative Resection for Esophageal Adenocarcinoma: Analysis Of 100 En Bloc Esophagectomies , 2001, Annals of surgery.

[177]  J. Richter,et al.  Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. , 1996, Gastroenterology.